On May 1, 2023 CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, reported that two abstracts have been accepted for presentation at the upcoming 2023 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting taking place June 2-6, 2023 in Chicago, IL (Press release, CTI BioPharma, MAY 1, 2023, View Source [SID1234630766]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation details are as follows:
Title: Spleen volume reduction (SVR) predicts overall survival (OS) in myelofibrosis (MF) patients on pacritinib (PAC) but not best available therapy (BAT): PERSIST-2 landmark OS analysis
Abstract #: 7018
Presenter: Helen Ajufo, M.D., Memorial Sloan Kettering Cancer Center
Session Title: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Session Date and Time: Monday, June 5, 2023, 8:00 – 11:00 a.m. CT
Location: Hall A, Poster #148
Poster discussion: In addition to the poster presentation, Dr. Ajufo will host a poster discussion session on Monday, June 5, 2023 from 11:30 a.m. – 1:00 p.m. CT in Room E450.
Title: Consistency of pacritinib for spleen and symptom reduction in patients with myelofibrosis regardless of cytopenias
Abstract #: 7068
Presenter: Dr. Prithviraj Bose, M.D., The University of Texas MD Anderson Cancer Center
Session Title: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Session Date and Time: Monday, June 5, 2023, 8:00 – 11:00 a.m. CT
Location: Hall A, Poster #198